Lucas Chun Wah Fong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lucas Chun Wah Fong has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ming-Yen Ng
Department of Diagnostic Radiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2 shared publications Andrew T. Yan
Department of Medicine, University of Toronto Division of Cardiology, St. Michael’s Hospital, Toronto, Ontario, Canada
1 shared publication- Bruno Roza da Costa
Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, United Kingdom (B.R.C.).
1 shared publication - Colin Berry
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
1 shared publication - Dudley John Pennell
National Heart and Lung Institute, Imperial College London
1 shared publication - Hok Shing Tang
Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, China
1 shared publication
Latest Publications
- Open Access
- 5 November 2021
- Published by S. Karger AG in Cardiology
- Vol. 147 (1) , 1-13
Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Introduction: There have been inconsistent data on the direct comparison of prasugrel and ticagrelor. This meta-analysis was conducted to summarize the current available evidence. Methods: We performed a meta-analysis (PROSPERO-registered CRD42020166810) of randomized trials up to February 2020 that compared prasugrel and ticagrelor in acute coronary syndrome with respect to the composite endpoint of myocardial infarction (MI), stroke, or cardiovascular death and secondary endpoints including MI, stroke, cardiovascular death, major bleeding (Bleeding Academic Research Consortium (BARC) type 2 or above), stent thrombosis, all-cause death, and other safety outcomes. Results: Of the 11 eligible RCTs with 6,098 patients randomized to prasugrel (n = 3,050) or ticagrelor (n = 3,048), 180 and 207 had the composite endpoint events in the prasugrel arm and the ticagrelor arm, respectively, over a weighted mean follow-up period of 11 ± 2 months. Compared with prasugrel, the ticagrelor group had similar risk in the primary composite endpoint (risk ratio [RR] = 1.17; 95% CI = 0.96–1.42; p = 0.12, I2 = 0%). Compared to prasugrel, there was no significant difference associated with the ticagrelor groups with respect to stroke (RR = 1.05; 95% CI = 0.66–1.67; p = 0.84, I2 = 0%), cardiovascular death (RR = 1.01; 95% CI = 0.75–1.36; p = 0.95, I2 = 0%), BARC type 2 or above bleeding (RR = 1.16; 95% CI = 0.89–1.52; p = 0.26, I2 = 0%), stent thrombosis (RR = 1.58; 95% CI = 0.90–2.76; p = 0.11, I2 = 0%), and all-cause death (RR = 1.10; 95% CI = 0.86–1.43; p = 0.45, I2 = 0%) except MI (RR = 1.38; 95% CI = 1.05–1.81; p = 0.02, I2 = 0%) Conclusion: Compared with prasugrel, ticagrelor did not reduce the primary composite endpoint of MI, stroke, and cardiovascular death at a weighted mean follow-up of 11 months. There was no significant difference between the secondary outcomes except MI.
- 5 November 2021
- Published by S. Karger AG in Cardiology
- Vol. 147 (1) , 1-13
Open AccessComparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Introduction: There have been inconsistent data on the direct comparison of prasugrel and ticagrelor. This meta-analysis was conducted to summarize the current available evidence. Methods: We performed a meta-analysis (PROSPERO-registered CRD42020166810) of randomized trials up to February 2020 that compared prasugrel and ticagrelor in acute coronary syndrome with respect to the composite endpoint of myocardial infarction (MI), stroke, or cardiovascular death and secondary endpoints including MI, stroke, cardiovascular death, major bleeding (Bleeding Academic Research Consortium (BARC) type 2 or above), stent thrombosis, all-cause death, and other safety outcomes. Results: Of the 11 eligible RCTs with 6,098 patients randomized to prasugrel (n = 3,050) or ticagrelor (n = 3,048), 180 and 207 had the composite endpoint events in the prasugrel arm and the ticagrelor arm, respectively, over a weighted mean follow-up period of 11 ± 2 months. Compared with prasugrel, the ticagrelor group had similar risk in the primary composite endpoint (risk ratio [RR] = 1.17; 95% CI = 0.96–1.42; p = 0.12, I2 = 0%). Compared to prasugrel, there was no significant difference associated with the ticagrelor groups with respect to stroke (RR = 1.05; 95% CI = 0.66–1.67; p = 0.84, I2 = 0%), cardiovascular death (RR = 1.01; 95% CI = 0.75–1.36; p = 0.95, I2 = 0%), BARC type 2 or above bleeding (RR = 1.16; 95% CI = 0.89–1.52; p = 0.26, I2 = 0%), stent thrombosis (RR = 1.58; 95% CI = 0.90–2.76; p = 0.11, I2 = 0%), and all-cause death (RR = 1.10; 95% CI = 0.86–1.43; p = 0.45, I2 = 0%) except MI (RR = 1.38; 95% CI = 1.05–1.81; p = 0.02, I2 = 0%) Conclusion: Compared with prasugrel, ticagrelor did not reduce the primary composite endpoint of MI, stroke, and cardiovascular death at a weighted mean follow-up of 11 months. There was no significant difference between the secondary outcomes except MI.
- Open Access
- 1 January 2021
- Published by Asian Society of Cardiovascular Imaging in Cardiovascular Imaging Asia
- Vol. 5 (3) , 83-93
Invasive and Non-Invasive Imaging for Ischaemia with No Obstructive Coronary Artery Disease
Ng MY, et al. Cardiovasc Imaging Asia. 2021 Jul;5(3):83-93. https://doi.org/10.22468/cvia.2021.00129
- 1 January 2021
- Published by Asian Society of Cardiovascular Imaging in Cardiovascular Imaging Asia
- Vol. 5 (3) , 83-93
Open AccessInvasive and Non-Invasive Imaging for Ischaemia with No Obstructive Coronary Artery Disease
Ng MY, et al. Cardiovasc Imaging Asia. 2021 Jul;5(3):83-93. https://doi.org/10.22468/cvia.2021.00129
- Open Access
- 21 July 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (14) , e015361
Bias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
Background: Loss to follow‐up ( LTFU ) is common in randomized controlled trials. However, its potential impact on primary outcomes from cardiovascular randomized controlled trials is not known. Methods and Results: We conducted a prospective systematic review ( PROSPERO : CRD 42019121959) for randomized controlled trials published in 8 leading journals over 5 years from January 2014 to December 2018. Extent, reporting, and handling of LTFU data were recorded, and the proportion of a trial's primary outcome results that lose statistical significance was calculated after making plausible assumptions for the intervention and control arms. These assumptions could drive differential treatment effects between the groups considering relative event incidence between LTFU participants and those included in the primary outcome. We identified 117 randomized controlled trials of which 91 (78%) trials reported LTFU , 23 (20%) reported no LTFU , and 3 (3%) trials did not report on whether LTFU occurred. The median percentage of study participants lost to follow‐up was 2% (interquartile range, 0.33%–5.3%). Only 10 trials (9%) had a low cluster of risk factors for impairment in trial quality. The percentage of trials losing statistical significance varied from 2% when the relative event incidence for LTFU between the randomized groups was 1 for the intervention arm and 1.5 for the control arm to 16% when the relative event incidence was 3 for the intervention arm and 1 for the control arm. Conclusions: Almost 1 in 6 (16%) cardiovascular randomized trials published in leading journals may have a change in the primary outcome if plausible assumptions are made about differential event rates of participants lost to follow up. There is scope for improvement arising from LTFU in randomized trials in cardiovascular medicine. Registration: URL : https://www.crd.york.ac.uk/prospero ; Unique identifier: CRD 42019121959.
- 21 July 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (14) , e015361
Open AccessBias and Loss to Follow‐Up in Cardiovascular Randomized Trials: A Systematic Review
Background: Loss to follow‐up ( LTFU ) is common in randomized controlled trials. However, its potential impact on primary outcomes from cardiovascular randomized controlled trials is not known. Methods and Results: We conducted a prospective systematic review ( PROSPERO : CRD 42019121959) for randomized controlled trials published in 8 leading journals over 5 years from January 2014 to December 2018. Extent, reporting, and handling of LTFU data were recorded, and the proportion of a trial's primary outcome results that lose statistical significance was calculated after making plausible assumptions for the intervention and control arms. These assumptions could drive differential treatment effects between the groups considering relative event incidence between LTFU participants and those included in the primary outcome. We identified 117 randomized controlled trials of which 91 (78%) trials reported LTFU , 23 (20%) reported no LTFU , and 3 (3%) trials did not report on whether LTFU occurred. The median percentage of study participants lost to follow‐up was 2% (interquartile range, 0.33%–5.3%). Only 10 trials (9%) had a low cluster of risk factors for impairment in trial quality. The percentage of trials losing statistical significance varied from 2% when the relative event incidence for LTFU between the randomized groups was 1 for the intervention arm and 1.5 for the control arm to 16% when the relative event incidence was 3 for the intervention arm and 1 for the control arm. Conclusions: Almost 1 in 6 (16%) cardiovascular randomized trials published in leading journals may have a change in the primary outcome if plausible assumptions are made about differential event rates of participants lost to follow up. There is scope for improvement arising from LTFU in randomized trials in cardiovascular medicine. Registration: URL : https://www.crd.york.ac.uk/prospero ; Unique identifier: CRD 42019121959.